16 results on '"Hongeng, Suradej"'
Search Results
2. In Vitro Study of Ineffective Erythropoiesis in Thalassemia: Diverse Intrinsic Pathophysiological Features of Erythroid Cells Derived from Various Thalassemia Syndromes.
- Author
-
Kaewsakulthong, Woratree, Suriyun, Thunwarat, Chumchuen, Sukanya, Anurathapan, Usanarat, Hongeng, Suradej, Fucharoen, Suthat, and Sripichai, Orapan
- Subjects
THALASSEMIA ,ERYTHROPOIESIS ,CELL death ,CELL differentiation ,GLOBIN - Abstract
Defective hemoglobin production and ineffective erythropoiesis contribute to the pathophysiology of thalassemia syndromes. Previous studies in the field of erythropoiesis mainly focused on the severe forms of thalassemia, such as β-thalassemia major, while mechanisms underlying the pathogenesis of other thalassemia syndromes remain largely unexplored. The current study aimed to investigate the intrinsic pathophysiological properties of erythroid cells derived from the most common forms of thalassemia diseases, including α-thalassemia (hemoglobin H and hemoglobin H-Constant Spring diseases) and β-thalassemia (homozygous β
0 -thalassemia and β0 -thalassemia/hemoglobin E diseases), under an identical in vitro erythroid culture system. Cell proliferation capacity, differentiation velocity, cell death, as well as globin synthesis and the expression levels of erythropoiesis modifying factors were determined. Accelerated expansion was found in erythroblast cells derived from all types of thalassemia, with the highest degree in β0 -thalassemia/hemoglobin E. Likewise, all types of thalassemia showed limited erythroid cell differentiation, but each of them manifested varying degrees of erythroid maturation arrest corresponding with the clinical severity. Robust induction of HSP70 transcripts, an erythroid maturation-related factor, was found in both α- and β-thalassemia erythroid cells. Increased cell death was distinctly present only in homozygous β0 -thalassemia erythroblasts and associated with the up-regulation of pro-apoptotic (Caspase 9, BAD, and MTCH1) genes and down-regulation of the anti-apoptotic BCL-XL gene. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
3. Haploidentical Hematopoietic Stem Cell Transplantation in Thalassemia.
- Author
-
Anurathapan, Usanarat, Pakakasama, Samart, Songdej, Duantida, Pongphitcha, Pongpak, Chuansumrit, Ampaiwan, Andersson, Borje S., and Hongeng, Suradej
- Subjects
HEMATOPOIETIC stem cell transplantation ,THALASSEMIA ,HLA histocompatibility antigens - Abstract
Allogeneic hematopoietic stem cell transplantation (HSCT) is the only established treatment that is potentially curative, but it is limited by the availability of donors and the medical condition of the patient. To expand the donor pool to include haploidentical related donors, we introduced a program consisting of a pharmacologic pre transplant immune suppression phase (PTIS) and two courses of dexamethasone (DXM) and fludarabine (FLU) followed by pre transplant conditioning with intravenous FLU busulfan (BU) and post transplant graft-vs.-host disease (GvHD) prophylaxis with cyclophosphamide (CPM), tacrolimus, and mycophenolate mofetil. We transplanted 83 consecutive transfusion-dependent patients with thalassemia; the 3-year projected overall and event-free survival is over 96.0%, and there have been no secondary graft failures. Of the first 31 patients, we had two graft failures, both of them occurring in patients with extremely high titers of anti-donor-specific human leukocyte antigen (HLA) antibodies [anti-donor specific antibodies (DSAs)], but after adjusting the PTIS to include bortezomib (BORT) and rituximab (RIX) for patients with high titers of anti-DSAs and using pharmacologic dose guidance for BU, we had no graft failures in the last 52 patients. Six (7.0%) of 83 patients developed severe GvHD. We conclude that this is a safe and efficacious approach to allogeneic HSCT in thalassemia. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
4. Cost utility analysis of reduced intensity hematopoietic stem cell transplantation in adolescence and young adult with severe thalassemia compared to hypertransfusion and iron chelation program
- Author
-
Sruamsiri Rosarin, Chaiyakunapruk Nathorn, Pakakasama Samart, Sirireung Somtawin, Sripaiboonkij Nintita, Bunworasate Udomsak, and Hongeng Suradej
- Subjects
Cost-utility analysis ,Reduced intensity transplantation ,Thalassemia ,Adolescence ,Adult ,Public aspects of medicine ,RA1-1270 - Abstract
Abstract Background Hematopoieticic stem cell transplantation is the only therapeutic option that can cure thalassemia disease. Reduced intensity hematopoietic stem cell transplantation (RI-HSCT) has demonstrated a high cure rate with minimal complications compared to other options. Because RI-HSCT is very costly, economic justification for its value is needed. This study aimed to estimate the cost-utility of RI-HSCT compared with blood transfusions combined with iron chelating therapy (BT-ICT) for adolescent and young adult with severe thalassemia in Thailand. Methods A Markov model was used to estimate the relevant costs and health outcomes over the patients’ lifetimes using a societal perspective. All future costs and outcomes were discounted at a rate of 3% per annum. The efficacy of RI-HSCT was based a clinical trial including a total of 18 thalassemia patients. Utility values were derived directly from all patients using EQ-5D and SF-6D. Primary outcomes of interest were lifetime costs, quality adjusted life-years (QALYs) gained, and the incremental cost-effectiveness ratio (ICER) in US ($) per QALY gained. One-way and probabilistic sensitivity analyses (PSA) were conducted to investigate the effect of parameter uncertainty. Results In base case analysis, the RI-HSCT group had a better clinical outcomes and higher lifetime costs. The incremental cost per QALY gained was US $ 3,236 per QALY. The acceptability curve showed that the probability of RI-HSCT being cost-effective was 71% at the willingness to pay of 1 time of Thai Gross domestic product per capita (GDP per capita), approximately US $ 4,210 per QALY gained. The most sensitive parameter was utility of severe thalassemia patients without cardiac complication patients. Conclusion At a societal willingness to pay of 1 GDP per capita, RI-HSCT was a cost-effective treatment for adolescent and young adult with severe thalassemia in Thailand compared to BT-ICT.
- Published
- 2013
- Full Text
- View/download PDF
5. Hematopoietic Stem Cell Transplantation for Severe Thalassemia Patients from Haploidentical Donors Using a Novel Conditioning Regimen.
- Author
-
Anurathapan, Usanarat, Hongeng, Suradej, Pakakasama, Samart, Songdej, Duantida, Sirachainan, Nongnuch, Pongphitcha, Pongpak, Chuansumrit, Ampaiwan, Charoenkwan, Pimlak, Jetsrisuparb, Arunee, Sanpakit, Kleebsabai, Rujkijyanont, Piya, Meekaewkunchorn, Arunotai, Lektrakul, Yujinda, Iamsirirak, Pornchanok, Surapolchai, Pacharapan, Sirireung, Somtawin, Sruamsiri, Rosarin, Wahidiyat, Pustika Amalia, and Andersson, Borje S.
- Subjects
- *
BUSULFAN , *HEMATOPOIETIC stem cell transplantation , *ALEMTUZUMAB , *RITUXIMAB , *THALASSEMIA , *TOTAL body irradiation , *STEM cell transplantation , *GRAFT rejection - Abstract
• Allogeneic stem cell transplant (SCT) is curative for patients with severe thalassemia. It can be safely performed with a sequence of a pretransplant immunosuppressive therapy (PTIS) of pulse fludarabine and dexamethasone, followed by a reduced-intensity regimen of fludarabine and i.v. busulfan, as well as peripheral blood progenitor transplant with post-transplant cyclophosphamide-based immunosuppression. • Patients with very high titers of anti-donor-specific antibodies (1:3000) further benefited from the addition of bortezomib and Rituxan to the PTIS phase to alleviate antibody-mediated graft rejection. • With this approach, SCT now be safely carried out using both matched and mismatched (aka haploidentical) donors, with a 3-year event-free and overall survival of 95%, regardless of donor type, and without having any increased risk for mortality in patients who are older than 7 years and having hepatomegaly (i.e., the Lucarelli group III high-risk subset). • This demonstrates that there is no reason to take the risk(s) of total body irradiation to secure engraftment in this group of patients who are at high risk for graft failure. Patients with severe thalassemia commonly have a survival that is significantly shorter than that of the general population. Allogeneic hematopoietic stem cell transplantation (allo-SCT) is the only established treatment that is potentially curative, but it is limited by the availability of donors and the medical condition of the patient. To expand the donor pool to include haploidentical related donors, we introduced a program consisting of a pharmacologic pretransplant immune suppression phase (PTIS) and 2 courses of dexamethasone and fludarabine, followed by pretransplant conditioning with fludarabine-i.v. busulfan and post-transplant graft-versus-host disease (GVHD) prophylaxis with cyclophosphamide, tacrolimus, and mycophenolate mofetil. We transplanted 83 consecutive transfusion-dependent patients with thalassemia (median age, 12 years; range, 1 to 28 years) with a minimum follow-up of 6 months (median, 15 months; range, 7 to 53 months); the 3-year projected overall and event-free survival is over 96%, and there have been no secondary graft failures. Of the first 31 patients, we had 2 graft failures, both of them occurring in patients with extremely high titers of anti-donor-specific HLA antibodies (anti-DSAs), but after adjusting the PTIS to include bortezomib and rituximab for patients with high titers of anti-DSAs and using pharmacologic dose guidance for busulfan, we had no graft failures in the last 52 patients. Six (7%) of 83 patients developed severe GVHD. We conclude that this is a safe and efficacious approach to allogeneic SCT in thalassemia, yielding results comparable to those available for patients with fully matched donors. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
6. Acetazolamide aggravated diabetic ketoacidosis severity in a boy post-transplantation thalassaemia with intracranial hypertension.
- Author
-
Sakornyutthadej, Natee, Mahachoklertwattana, Pat, Anantasit, Nattachai, Hongeng, Suradej, and Poomthavorn, Preamrudee
- Subjects
INTRACRANIAL hypertension ,DIABETIC acidosis ,ACETAZOLAMIDE ,CENTRAL nervous system infections ,THALASSEMIA - Abstract
Owing to the rarity of DKA as compared with the other causes of headache in this particular patient, the DKA diagnosis was missed. Intracranial hypertension could be a presenting symptom of diabetic ketoacidosis. Acetazolamide aggravated diabetic ketoacidosis severity in a boy post-transplantation thalassaemia with intracranial hypertension. [Extracted from the article]
- Published
- 2021
- Full Text
- View/download PDF
7. Investigation of FoxO3 dynamics during erythroblast development in β-thalassemia major.
- Author
-
Thanuthanakhun, Naruchit, Nuntakarn, Lalana, Sampattavanich, Somponnat, Anurathapan, Usanarat, Phuphanitcharoenkun, Suphanun, Pornpaiboonstid, Savichaya, Borwornpinyo, Suparerk, and Hongeng, Suradej
- Subjects
THALASSEMIA ,ERYTHROPOIESIS ,PROGENITOR cells ,FLOW cytometry ,PHOSPHORYLATION - Abstract
The FoxO3 transcription factor is a key regulator of oxidative stress and erythroid maturation during erythropoiesis. In this study, we explored the involvement of FoxO3 in severe β-thalassemia. Using primary CD34
+ hematopoietic progenitor cells from patients with β-thalassemia major, we successfully developed an in vitro model of ineffective erythropoiesis. Based on this model, FoxO3 activity was quantified in single cells using high throughput imaging flow cytometry. This study revealed a significant reduction of FoxO3 activity during the late stage of erythroblast differentiation in β-thalassemia, in contrast to erythropoiesis in normal cells that maintain persistent activation of FoxO3. In agreement with the decreased FoxO3 activity in β-thalassemia, the expression of FoxO3 target genes was also found to decrease, concurrent with elevated phosphorylation of AKT, most clearly at the late stage of erythroid differentiation. Our findings provide further evidence for the involvement of FoxO3 during terminal erythropoiesis and confirm the modulation of the PI3K/AKT pathway as a potential therapeutic strategy for β-thalassemia. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
8. Normalized levels of red blood cells expressing phosphatidylserine, their microparticles, and activated platelets in young patients with β-thalassemia following bone marrow transplantation.
- Author
-
Klaihmon, Phatchanat, Vimonpatranon, Sinmanus, Noulsri, Egarit, Lertthammakiat, Surapong, Anurathapan, Usanarat, Sirachainan, Nongnuch, Hongeng, Suradej, and Pattanapanyasat, Kovit
- Subjects
BONE marrow transplantation ,ERYTHROCYTES ,PHOSPHATIDYLSERINES ,BLOOD platelets ,BLOOD transfusion ,THALASSEMIA ,ERYTHROCYTE metabolism ,BLOOD platelet activation ,CALCIUM-binding proteins ,CELL membranes ,CLINICAL trials ,COMPARATIVE studies ,HOMOGRAFTS ,RESEARCH methodology ,MEDICAL cooperation ,PHOSPHOLIPIDS ,RESEARCH ,EVALUATION research ,BETA-Thalassemia ,THERAPEUTICS - Abstract
Bone marrow transplantation (BMT) serves as the only curative treatment for patients with β-thalassemia major; however, hemostatic changes have been observed in these BMT patients. Aggregability of thalassemic red blood cells (RBCs) and increased red blood cell-derived microparticles (RMPs) expressing phosphatidylserine (PS) are thought to participate in thromboembolic events by initially triggering platelet activation. To our knowledge, there has been no report providing quantitation of these circulating PS-expressing RBCs and RMPs in young β-thalassemia patients after BMT. Whole blood from each subject was fluorescently labeled to detect RBC markers (CD235a) and annexin-V together with the known number TruCount™ beads. PS-expressing RBCs, RMPs, and activated platelets were identified by flow cytometry. In our randomized study, we found the decreased levels of three aforementioned factors compared to levels in patients receiving regular blood transfusion (RT). This study showed that BMT in β-thalassemia patients decreases the levels of circulating PS-expressing RBCs, their MPs, and procoagulant platelets when compared to patients who received RT. Normalized levels of these coagulation markers may provide the supportive evidence of the effectiveness of BMT for curing thalassemia. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
9. Protection against Oxidative Stress in Beta Thalassemia/Hemoglobin E Erythrocytes by Inhibitors of Glutathione Efflux Transporters.
- Author
-
Muanprasat, Chatchai, Wongborisuth, Chokdee, Pathomthongtaweechai, Nutthapoom, Satitsri, Saravut, and Hongeng, Suradej
- Subjects
THALASSEMIA ,HEMOGLOBINS ,OXIDATIVE stress ,ERYTHROCYTES ,PROTEINS ,MOLECULES - Abstract
In beta thalassemia/hemoglobin E (Hb E), abnormally high levels of oxidative stress account for accelerated senescence and increased destruction of erythrocytes. The present study aimed to investigate the role of glutathione efflux transporters, namely cystic fibrosis transmembrane conductance regulator (CFTR) and multidrug resistance-associated protein 1 (MRP1), in the control of glutathione levels and protection against oxidative challenges in beta thalassemia/Hb E erythrocytes. We found that CFTR protein was expressed in the erythrocytes of beta thalassemia/Hb E patients. Treatments with GlyH-101 (50 µM), a small molecule CFTR inhibitor, and MK571 (50 µM), an MRP1 inhibitor, reduced H
2 O2 -induced free radical generation in the erythrocytes by ~80% and 50%, respectively. Furthermore, combined treatment with GlyH-101 and MK571 completely abolished the induction of reactive oxygen radicals. Increased oxidative stress in the erythrocytes following H2 O2 challenges was accompanied by a decrease in intracellular level of reduced glutathione (GSH), which was prevented by treatments with GlyH-101 and MK571. CMFDA-based assays revealed that GlyH-101 and MK571 reduced H2 O2 - induced glutathione efflux from the erythrocytes by 87% and 66%, respectively. Interestingly, H2 O2 -induced osmotic tolerance of erythrocytes, a sign of erythrocyte aging, was ameliorated by treatment with GlyH-101. Our study indicates that oxidative stress induces glutathione efflux via CFTR and MRP1 in beta thalassemia/Hb E erythrocytes. Pharmacological inhibition of glutathione efflux represents a potential therapy to delay aging and premature destruction of erythrocytes in beta thalassemia/Hb E. [ABSTRACT FROM AUTHOR]- Published
- 2013
- Full Text
- View/download PDF
10. A cost-utility and budget impact analysis ofallogeneic hematopoietic stem celltransplantation for severe thalassemic patients inThailand.
- Author
-
Leelahavarong, Pattara, Chaikledkaew, Usa, Hongeng, Suradej, Kasemsup, Vijj, Lubell, Yoel, and Teerawattananon, Yot
- Subjects
HEMATOPOIETIC stem cells ,STEM cell transplantation ,THALASSEMIA ,BLOOD cells - Abstract
Background: Hematopoietic stem cell transplantation (HSCT) is the only curative treatment available to severe thalassemic patients. The treatment, however, is very costly, particularly in the context of low and middle income countries, and no studies have been carried out to explore its economic justifiability. This study aimed to estimate the cost-utility of HSCT compared with blood transfusions combined with iron chelating therapy (BT-ICT) for severe thalassemia in Thailand, and to investigate the affordability of HSCT using a budget impact analysis. Methods: A Markov model was used to estimate the relevant costs and health outcomes over the patients' lifetimes taking a societal perspective as recommended by Thailand's health technology assessment guidelines. All future costs and outcomes were discounted at a rate of 3% per annum. Primary outcomes of interest were lifetime costs, quality adjusted life years (QALYs) gained, and the incremental cost-effectiveness ratio (ICER) in Thai baht (THB) per QALY gained. Results: Compared to BT-ICT, the incremental cost-effectiveness ratio increased with patient age from 80,700 to 183,000 THB per QALY gained for related HSCT and 209,000 to 953,000 THB per QALY gained for unrelated HSCT among patients aged 1 to 15 years (US$1= 34 THB). The governmental budget impact analysis showed that providing 200 related HSCT to patients aged 1 to 10 years, in accordance with the current infrastructure limitations, would initially require approximately 90 million additional THB per year. Conclusions: At a societal willingness to pay of 100,000 THB per QALY gained, related HSCT was likely to be a cost-effective and affordable treatment for young children with severe thalassemia in Thailand. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
11. Outcomes of Transplantation with Related- and Unrelated-Donor Stem Cells in Children with Severe Thalassemia
- Author
-
Hongeng, Suradej, Pakakasama, Samart, Chuansumrit, Ampaiwan, Sirachainan, Nongnuch, Kitpoka, Pimpan, Udomsubpayakul, Umaporn, Ungkanont, Artit, and Jootar, Saengsuree
- Subjects
- *
HEMOGLOBINOPATHY , *HEMOLYTIC anemia , *CELLULAR therapy , *THALASSEMIA - Abstract
Abstract: Recently published reports indicate that the outcome of unrelated donor transplantations in patients with leukemia is currently comparable to that of transplantation from identical family donors. We investigated the possibly favorable outcomes of related and unrelated transplantation in children with severe thalassemia. We reviewed transplantation outcome in 49 consecutive children with severe thalassemia who underwent allogeneic stem cell transplantation with related-donor (n = 28) and unrelated-donor (n = 21) stem cells between September 1992 and May 2005 at the Faculty of Medicine, Ramathibodi Hospital, Mahidol University (Bangkok, Thailand). Analysis of engraftment, frequency of procedure-related complications, and thalassemia-free survival showed no advantage from use of related-donor stem cells. The 2-year thalassemia-free survival estimate for recipients of related-donor stem cells was 82% compared with 71% in the unrelated-donor stem cell group (P = .42). The present study provides evidence to support the view that it is quite reasonable to consider unrelated-donor stem cell transplantation an acceptable therapeutic approach in severe thalassemia, at least for patients who are not fully compliant with conventional treatment and do not yet show irreversible severe complications of iron overload. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
12. The second mini-transplant for unstable mixed chimerism within the first 100 days after hematopoietic stem cell transplant in severe thalassemia.
- Author
-
Choeyprasert, Worawut, Pakakasama, Samart, Anurathapan, Usanarat, Songdej, Duantida, Sirachainun, Nongnuch, Sirireung, Somtawin, Panthangkool, Wanpen, and Hongeng, Suradej
- Subjects
CHIMERISM ,HEMATOPOIETIC stem cell transplantation ,THALASSEMIA in children ,GRAFT rejection ,HEMOGLOBINS ,THERAPEUTICS - Abstract
Choeyprasert W, Pakakasama S, Anurathapan U, Songdej D, Sirachainun N, Sirireung S, Panthangkool W, Hongeng S. The second mini-transplant for unstable mixed chimerism within the first 100 days after hematopoietic stem cell transplant in severe thalassemia. Pediatr Transplantation 2011. © 2011 John Wiley & Sons A/S. Abstract: Allogeneic HSCT is the only curative treatment for severe thalassemia disease. MC occurs in one-third of these patients within the first two months after HSCT; this is a major risk factor of graft rejection, especially when RHCs are more than 25%. There is still no consensus for the management of MC, especially in the early phase of HSCT. The DLI has also been described in the treatment of MC following HSCT for hemoglobinopathies, but its success is still not guaranteed. The second HSCT has been an approach used in an attempt to cure patients who reject their graft. Concern about toxicity of conditioning regimen, the second HSCT is usually delayed for at least a year after the first HSCT. We would like to demonstrate the successful use of the second mini-allogeneic HSCT in hemoglobin E/β-thalassemia with evidence of unstable MC in the first 100 days after allogeneic HSCT to prevent further graft loss after allogeneic HSCT. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
13. A Novel Approach of Hematopoietic Stem Cell Transplantation for Severe Thalassemia from Haploidentical Donors with Favorable Outcomes.
- Author
-
Anurathapan, Usanarat, Hongeng, Suradej, Pakakasama, Samart, Sirachainan, Nongnuch, Songdej, Duantida, Chuansumrit, Ampaiwan, and Andersson, Borje S.
- Subjects
- *
HEMATOPOIETIC stem cell transplantation , *THALASSEMIA , *ORGAN donors , *HEALTH outcome assessment , *CLINICAL trials - Published
- 2016
- Full Text
- View/download PDF
14. Haploidentical Hematopoietic Stem Cell Transplantation (Haplo-SCT) with Pre-Transplant Immunosuppression and Post-Transplant Cyclophosphamide (Post-Cy) in Severe Thalassemia: A Novel Approach Transplant for Nonmalignant Diseases.
- Author
-
Hongeng, Suradej, Pakakasama, Samart, Anurathapan, Usanarat, and Andersson, Borje S.
- Subjects
- *
HEMATOPOIETIC stem cell transplantation , *IMMUNOSUPPRESSION , *CYCLOPHOSPHAMIDE , *THALASSEMIA , *MEDICAL research - Published
- 2015
- Full Text
- View/download PDF
15. Outcomes of Thalassemia Patients Undergoing Hematopoietic Stem Cell Transplantation by Using a Standard Myeloablative versus a Novel Reduced-Toxicity Conditioning Regimen According to a New Risk Stratification.
- Author
-
Anurathapan, Usanarat, Pakakasama, Samart, Mekjaruskul, Pimsiri, Sirachainan, Nongnuch, Songdej, Duantida, Chuansumrit, Ampaiwan, Charoenkwan, Pimlak, Jetsrisuparb, Arunee, Sanpakit, Kleebsabai, Pongtanakul, Bunchoo, Rujkijyanont, Piya, Meekaewkunchorn, Arunotai, Sruamsiri, Rosarin, Ungkanont, Artit, Issaragrisil, Surapol, Andersson, Borje S., and Hongeng, Suradej
- Subjects
- *
HEMATOPOIETIC stem cell transplantation , *THALASSEMIA treatment , *HEPATOMEGALY , *HEALTH outcome assessment , *CANCER chemotherapy - Abstract
Improving outcomes among class 3 thalassemia patients receiving allogeneic hematopoietic stem cell transplantations (HSCT) remains a challenge. Before HSCT, patients who were ≥ 7 years old and had a liver size ≥ 5 cm constitute what the Center for International Blood and Marrow Transplant Research defined as a very high–risk subset of a conventional high-risk class 3 group (here referred to as class 3 HR). We performed HSCT in 98 patients with related and unrelated donor stem cells. Seventy-six of the patients with age < 10 years received the more conventional myeloablative conditioning (MAC) regimen (cyclophosphamide, busulfan, ± fludarabine); the remaining 22 patients with age ≥ 10 years and hepatomegaly (class 3 HR), and in several instances additional comorbidity problems, underwent HSCT with a novel reduced-toxicity conditioning (RTC) regimen (fludarabine and busulfan). We then compared the outcomes between these 2 groups (MAC versus RTC). Event-free survival (86% versus 90%) and overall survival (95% versus 90%) were not significantly different between the respective groups; however, there was a higher incidence of serious treatment-related complications in the MAC group, and although we experienced 6 graft failures in the MAC group (8%), there were none in the RTC group. Based on these results, we suggest that (1) class 3 HR thalassemia patients can safely receive HSCT with our novel RTC regimen and achieve the same excellent outcome as low/standard-risk thalassemia patients who received the standard MAC regimen, and further, (2) that this novel RTC approach should be tested in the low/standard-risk patient population. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
16. Pretransplant Immunosuppression followed by Reduced-Toxicity Conditioning and Stem Cell Transplantation in High-Risk Thalassemia: A Safe Approach to Disease Control.
- Author
-
Anurathapan, Usanarat, Pakakasama, Samart, Rujkijyanont, Piya, Sirachainan, Nongnuch, Songdej, Duantida, Chuansumrit, Ampaiwan, Sirireung, Somtawin, Charoenkwan, Pimlak, Jetsrisuparb, Arunee, Issaragrisil, Surapol, Ungkanont, Artit, Sruamsiri, Rosarin, Srisala, Supanart, Andersson, Borje S., and Hongeng, Suradej
- Subjects
- *
IMMUNOSUPPRESSION , *CANCER chemotherapy , *STEM cell transplantation , *THALASSEMIA , *PREVENTIVE medicine , *HEMATOPOIETIC stem cell transplantation , *DISEASE risk factors - Abstract
Abstract: Patients with class 3 thalassemia with high-risk features for adverse events after high-dose chemotherapy with hematopoietic stem cell transplantation (HSCT) are difficult to treat, tending to either suffer serious toxicity or fail to establish stable graft function. We performed HSCT in 18 such patients age ≥7 years and hepatomegaly using a novel approach with pretransplant immunosuppression followed by a myeloablative reduced-toxicity conditioning regimen (fludarabine and i.v. busulfan [Flu-IV Bu]) and then HSCT. The median patient age was 14 years (range, 10 to 18 years). Before the Flu-IV Bu + antithymocyte globulin conditioning regimen, all patients received 1 to 2 cycles of pretransplant immunosuppression with fludarabine and dexamethasone. Thirteen patients received a related donor graft, and 5 received an unrelated donor graft. An initial prompt engraftment of donor cells with full donor chimerism was observed in all 18 patients, but 2 patients developed secondary mixed chimerism that necessitated withdrawal of immunosuppression to achieve full donor chimerism. Two patients (11%) had acute grade III-IV graft-versus-host disease, and 5 patients had limited chronic graft-versus-host disease. The only treatment-related mortality was from infection, and with a median follow-up of 42 months (range, 4 to 75), the 5-year overall survival and thalassemia-free survival were 89%. We conclude that this novel sequential immunoablative pretransplantation conditioning program is safe and effective for patients with high-risk class 3 thalassemia exhibiting additional comorbidities. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.